Shanghai Jiao Tong University School of Medicine Tests Intranasal Umbilical Cord Exosomes for Early Parkinson’s Disease
A single-center Phase 1/2 dose-escalation study will assess whether intranasal exosomes from umbilical cord mesenchymal stromal cells are safe and tolerable, and whether they may improve motor and non-motor symptoms and imaging measures in adults with early Parkinson’s disease over 48 weeks.

Shanghai Jiao Tong University School of Medicine is sponsoring a Phase 1/2 trial to evaluate an intranasal spray of exosomes derived from umbilical cord mesenchymal stromal cells in adults with early Parkinson’s disease. The product, called UCMSC-Exo, is a cell-free liquid containing exosomes in saline and is given by nasal spray rather than intravenously.
The single-center, open-label, dose-escalation study uses a 3+3 design with no placebo and no blinding. Nine participants are already enrolled. Researchers are assessing whether the intranasal exosomes are safe and tolerable at escalating concentrations, and whether they may improve motor and non-motor symptoms, biomarkers, and imaging measures over a 48-week follow-up period.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
- Sponsor: Shanghai Jiao Tong University School of Medicine, China
- Phase/Status: Phase 1, Phase 2; Active not recruiting
- Indication: Early Parkinson’s disease in adults aged 50–75; actual enrollment of 9 participants
- Arms/Dosing: Low-dose intranasal UCMSC-Exo: 5×10^8 particles/mL, 0.4 mL total (200 µL/nostril; 2 sprays/nostril), twice weekly for 12 weeks. Medium-dose intranasal UCMSC-Exo: 1×10^9 particles/mL, same volume and schedule. High-dose intranasal UCMSC-Exo: 2×10^9 particles/mL, same volume and schedule. All doses given with usual dopaminergic therapy continued.
- Control: None
- Endpoints: Primary: incidence, severity, and relationship to study intervention of local and systemic adverse events and serious adverse events from first dose through Week 48, assessed at Weeks 4, 12, 16, and 48. Other planned assessments: changes in motor and non-motor symptoms, biomarkers, and imaging measures at Weeks 12, 16, 24, 36, and 48.
- Timing: Study start: October 28, 2024 (actual). Estimated primary completion: June 30, 2027. Estimated study completion: June 30, 2027.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Exogenus Therapeutics Leads €13M Consortium to Advance Umbilical Cord Blood Secretome Therapy for Osteoarthritis
Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes
Creative Medical Technology Holdings Reports 93% Response Rate in Six-Month Pilot Study of Investigational Ultrasome for Knee Osteoarthritis
New Trial – Mesenchymal Stem Cell Exosomes for Non-Dialysis Chronic Kidney Disease
NurExone and NanoPass Developing Stem Cell Exosomes for Eye and Skin Regeneration
Celularity to Manufacture MuseCell Innovations Therapies in the US
Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy Facility
Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies







